Ralimetinib dimesylate

N/A

Report date: 2024/08/01 20:00:04
NME

Base Information

Drug NameRalimetinib dimesylate
Drug Alias NameRalimetinibum雷利替尼雷美替尼LY-2228820LSN-2322600 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsMetastatic breast cancerNeoplasm MetastasisFallopian Tube Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFrance National Cancer InstituteEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerNeoplasm MetastasisFallopian Tube Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG